IGIV3I Grifols
Clinical Trial to Evaluate the Efficacy and the Safety of IGIV3I Grifols 10% (Human Intravenous Immunoglobulin) in Patients Diagnosed With Immune Thrombocytopenic Purpura
Постоянная ссылка: https://clinomir.ru/trials/nct/NCT00699140/
Источник: ClinicalTrials.gov (U.S. National Library of Medicine). Что откуда
Простыми словами
Словарь терминов- Фаза III — большое исследование: новый препарат сравнивают со стандартным лечением или плацебо, чтобы доказать пользу и безопасность.
- Исследование завершено, новых участников не набирают.
- Возраст участников: 18–82 лет. Остальные условия — в блоке «Кто может участвовать».
- По плану участвуют 18 чел. во всех странах исследования.
- Центров в реестре: 2 в одном городе. Список — ниже на странице.
- Плановая дата окончания (12.2013) уже прошла.
Пересказ собран автоматически из данных реестра, без оценки пользы и рисков. Подробно о рисках и пользе рассказывает врач центра перед подписанием согласия.
Кто может участвовать
Главное из критериев
- ИнфекцииВИЧ, гепатит B или C упомянуты в критериях невключения
Выбрано из текста реестра автоматически, по правилам — без ИИ. Решение об участии принимает врач центра по полному протоколу.
Полный текст критериев (на английском, как в ClinicalTrials.gov) · включение: 13 · невключение: 17
Критерии включения
- Be aged between 18 and 82 at the time of written consent.
- Have confirmed diagnosis of chronic ITP and fulfil all the following criteria:
- irrelevant history except for the symptoms of bleeding,
- pattern of bleedings associated with platelet disorders,
- physical examination irrelevant for the ITP, except for the signs of bleeding,
- isolated thrombocytopenia in the blood count; apart from thrombocytopenia, the blood count is normal for the patient's age, or if abnormal, readily explained,
- peripheral blood smear consistent with ITP: thrombocytopenia with platelets of normal size or slightly larger than normal, with absence of platelet clumps and giant platelets; normal red blood cell and white blood cell morphology,
- confirmed diagnosis of immune thrombocytopenic purpura or, when any abnormal finding is present, additional diagnostic evaluation excludes other causes of thrombocytopenia.
- Previous known diagnosis of ITP for at least 3 months.
- To show a platelet count platelet count ≤ 20x10\^9/L at the moment of the first infusion with the study product.
- Have read the patient information and consent sheet, agreed to participate in the trial, and signed the consent sheet.
- Be expected to receive treatment over 5 days and follow-up for 3 months.
- For women of childbearing age, use adequate contraceptive method such as oral contraceptives, intrauterine device or tubal ligation during one-month period after the first infusion in the study.
Критерии невключения
- Have immune thrombocytopenia secondary to other pathologies or drug mediated thrombocytopenia.
- Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test.
- Present important active bleeding due to other reasons apart from the ITP.
- Exhibit an identifiable alternative cause of their thrombocytopenia, such as splenomegaly, family thrombocytopenia, bacteraemia, sepsis or active infection requiring or not therapy.
- Are presenting renal dysfunction.
- Have non-controlled arterial hypertension.
- Have documented liver cirrhosis or any hepatic disorder with alanine aminotransferase (ALT) levels 2.5 times or more than the normal upper limit or bilirubin greater than 2 mg/dL.
- Are presenting a cardiac disease including a history of coronary artery disease, angina pectoris or congestive heart failure.
- Present known infection due to HIV or hepatitis C virus (HCV).
- Have been previously treated with IVIG or anti-D immunoglobulin being unresponsive.
- Have a history of serious adverse reactions or non-serious but frequent adverse reactions to intravenous immune globulin (IVIG) preparations or other products derived from blood.
- Have known allergies to any IGIV3I Grifols components, such as D-sorbitol.
- Are simultaneously participating in other clinical studies or have received an investigational drug in the 3 months prior to the start of the study.
- Have been involved in the present study and being treated with the formulation at 5% (IGIV3I Grifols 5%).
- Have conditions that might affect patient compliance.
- Are unable to provide a storage serum sample just before the first dose of IGIV3I Grifols.
- Are pregnant or nursing an infant child or unwilling to practice adequate birth control in 1-month period after the first infusion in the study.
Источник: ClinicalTrials.gov, NCT00699140 · запись обновлена в реестре 8 февраля 2016.
Дизайн и результаты
Что измеряют — первичные конечные точки (1), вторичных — 8
- Responder Patients — At any time during the study period (The platelet count was measured at Days 1-6, 10, 14. 21, 30, 60, 90).
Цель исследования
The purpose of this study is to determine whether IGIV3I Grifols 10% is effective in the treatment of immune thrombocytopenic purpura.
Где проходит
2 центра в 1 городеОткуда эта информация
-
ClinicalTrials.gov (U.S. National Library of Medicine) · NCT00699140 Официальный реестр (США) · загружено 9 ноября 2026Препарат, номер протокола, название, цель, фаза, статус, сроки, число участников, спонсор, центры
Сведения сведены и нормализованы порталом «Клиномир»: названия компаний и центров приведены к одному написанию. Нашли ошибку? Напишите нам — исправим.